Absynth signs deal to develop MRSA drugs


Biotech firm Absynth Biologics has signed a deal to work with German firm MorphoSys on new ways of treating MRSA.

The agreement will see the Sheffield-based company, owned by university intellectual property firm Fusion IP, give MorphoSys access to target molecules it has identified associated with a group of infections known as Staphylococcus aureas.

MorphoSys will develop antibodies which will be tested by Absynth which will also benefit from milestone payments and royalties.

Absynth chief executive Dr Fiona Marston said: "We are delighted to be collaborating with MorphoSys. The synergies between our technologies enhance the prospects of creating products to benefit patients suffering from Staphylococcus aureus infections."

Absynth, which develops products for preventing and treating bacterial infections, was set up in 2006 by Fusion IP on the back of scientific discoveries made in the University of Sheffield laboratories of Professor Simon Foster and Dr Jorge Garcia-Lara.

MorphoSys chief executive Simon Moroney said: "This collaboration brings together Absynth's novel proprietary targets and expertise in Staphylococcus aureus including MRSA and MorphoSys's expertise in the generation of antibody drugs. 

"We see these new targets as a very promising basis of antibody therapy for an increasingly serious medical problem."

Fusion IP, also based in Sheffield, was set up eight years ago and has long term agreements with the University of Sheffield and Cardiff University to commercialise their intellectual property.


100% thumbs up from 1 votes cast